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Studies based on molecular testing of oral/nasal swabs underestimate severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to issues with test sensitivity, 
test timing and selection bias. The objective of this study was to report the presence of SARS-
CoV-2 antibodies, consistent with previous infection. 
Design 
This multicentre observational cohort study, conducted between 16th April - 3rd July 2020 at 5 
UK sites, recruited children of healthcare workers, aged 2 to 15 years of age. Participants 
provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding 
unwell contacts and symptoms.  
Results 
1007 participants were enrolled, and 992 were included in the final analysis. The median age 
of participants was 10·1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 
antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported 
no symptoms prior to testing. The presence of antibodies and the mean antibody titre was not 
influenced by age. Following multivariable analysis four independent variables were identified 
as significantly associated with SARS-CoV-2 seropositivity: known infected household contact 
OR=10.9(95% CI: 6.1 to 19.6); fatigue OR=16.8(95% CI: 5.5 to 51.9); gastrointestinal 
symptoms OR=6.6(95% CI 3.0 to 13.8); and changes in sense of smell or taste OR=10.0(95% 
CI: 2.4 to 11.4).  
Discussion 
Children demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. 
Fatigue, gastrointestinal symptoms and changes in sense of smell or taste were the symptoms 
most strongly associated with SARS-CoV-1 antibody positivity.  
Registration 







During the first wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic in England, children accounted for just 1% of confirmed infections,(1) had a milder 
clinical course, and had a much lower mortality than adults (1-4), a pattern similar to other 
international settings (3,4). The reasons for this are unknown, but various hypotheses exist. 
Public health measures, such as school closures, may have minimised children’s exposure to 
SARS-CoV-2. It is also possible that children have a different immune response to the virus 
for example reduced expression of the ACE2 gene, the host receptor for SAR-CoV-2 virus in 
airway cells (5-7). 
 
Despite existing data, it is impossible to state accurately what proportion of children were 
infected with SARS-CoV-2 in the UK. Studies based on molecular testing of oral/nasal swabs 
with real-time reverse transcription polymerase chain reaction (RT-qPCR) underestimate 
infection due to issues with test sensitivity, timing of testing and selection bias due to only 
symptomatic individuals undergoing testing (8). A potentially more reliable method is to test 
for specific antibodies. Existing antibody tests typically detect immunoglobulin G (IgG or Total 
antibody) to either the nucleocapsid or spike proteins of the virus (9). Antibody testing has 
greater potential than RT-qPCR to detect previous asymptomatic/mildly symptomatic 
infection, and is not dependent on coinciding with active infection. Current best 
seroprevalence estimates from adults in the UK indicate that approximately 6.2% have 
antibodies consistent with previous SARS-CoV-2 infection (10). These findings are similar to 
other domestic and international seroprevalence studies (11-14).  
 
It is unclear what proportion of children are asymptomatic and which symptoms are most 
associated with paediatric SARS-CoV-2 infection. Estimates based on RT-qPCR testing of 
oral/nasal swabs suggest that cough or fever are the most common symptoms (15-20). 
However, these studies focus on symptomatic cohorts, introducing selection bias (15-20), 






The objective of this study was to report the presence, and titres, of SARS-CoV-2 antibodies 
in healthy children of healthcare workers across the UK and to report the symptomatology of 

























This multicentre observational prospective cohort study was designed to determine the 
seroprevalence of SARS-CoV-2 antibodies in healthy children, and report the symptomatology 
of infection. This study has been written in conjunction with the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) guidelines (21). The study protocol has 
undergone external peer review and is available as an open access publication (22).  
 
Setting 
Participants were recruited from 5 UK centres, in the 4 regions of the UK, between 16th April 
2020 and 3rd July 2020. The sites included tertiary NHS hospitals (Belfast, Cardiff, 
Manchester, and Glasgow) and a Public Health England site (London).  
 
Participants 
Children of healthcare workers, aged between 2 and 15 years at the time of recruitment, were 
eligible to participate. A “healthcare worker” was defined as a National Health Service (NHS) 
employee. Healthcare workers were categorised according to role, including whether that role 
involved patient facing activities. Approximately 150 non-patient facing staff were included to 
provide a comparison group, and to improve the generalisability of the results. Participants 
were identified at each participating NHS organisation using internal intranet advertisements 
and email circulars. Children were excluded if they were receiving antibiotics, had been 
admitted to hospital within the last 7 days, were receiving oral immunosuppressive treatment, 
or if ever diagnosed with a malignancy. 
 
Informed consent 
Informed consent was obtained, and assent given by children where possible. Participants 
were free to decline/withdraw consent at any time without providing a reason and without 





Assessments and procedures  
All children underwent phlebotomy performed by experienced paediatric medical and nursing 
professionals. Serum and/or plasma were tested for antibodies to SARS-CoV-2, in UKAS 
accredited laboratories using the following assays, which have been validated for use in adults 
(23-25): 
 
• Nucleocapsid assays - (Abbott Architect® SARS-CoV-2 IgG and Roche 
Elecsys® Anti-SARS-CoV-2 Total Antibody) 
• Spike protein assays – (DiaSorin LIAISON® SARS CoV-2 S1/S2 IgG assay) 
 
The Abbott, Roche and DiaSorin assays are highly specific for SARS-CoV-2 antibodies, using 
the manufacturer’s suggested cut-offs, with specificities of 1.00 (95% CI 0.98 to 1.00), 1.00 
(95% CI 0.99 to 1.00) and 0.98 (95% CI 0.96 to 0.99) respectively (23-25). They do however 
have lower sensitivities at 0.94 (95% CI 0.86 to 0.98), 0.84 (95% CI 0.75 to 0.91) and 0.64 
(95% CI 0.54 to 0.73) respectively (23-25). A summary of the tests used is provided in Table 
1. 
 
Study data were collected on a case report form (CRF) using REDCap (Research Electronic 
Data Capture) electronic data capture tools (26). Participants and their parents provided 
information at enrollment relating to age, sex, previous health and potential predictors of 
SARS-CoV-2 seropositivity including; known contact with individuals with COVID-19, contact 
with individuals who have been symptomatic and/or self-isolating and results of any diagnostic 
testing such as RT-qPCR testing/antibody testing. Participants and their parents also reported 
any symptoms and illness episodes since the onset of the pandemic in March but prior to the 
first clinic appointment. Data was collected relating to symptoms but not relating to time of 
onset or duration of illness. To minimise recall bias, data relating to exposures and illness 
episodes were collected blinded to antibody testing results. Copies of the CRFs used at 





Primary Outcome Measures 
 Presence of antibodies (IgG/Total antibody) to SARS-CoV-2 in serum or plasma reported 
as titres. 
 SARS-CoV-2 seropositivity defined as a positive antibody test using the manufacturer’s 
advised positivity cut-off.  
 
Secondary Outcome Measure 
 Predictors of SARS-CoV-2 positivity including reported symptoms.  
 
Sample Size Justification  
The study was powered to detect a change in seroprevalence of SARS-CoV-2 antibodies at 
3 time-points (enrollment, and 2 and 6 months following enrollment). To achieve this, 675 
participants were required (assuming alpha of, 0.05 and beta of 0.2). Allowing for 30% dropout 
rate, we aimed to recruit 900 participants from 5 sites. The data presented in this study reflects 
only the data collected at enrollment and the study is ongoing.  
 
Statistical analysis plan 
Variables including sex, age, parent role, symptomatology, household contacts, and SARS-
CoV-2 antibody prevalence were analysed using descriptive statistics (number and proportion 
for discrete variables, median and interquartile range for continuous variables). 
Seroprevalence rates between sites were compared using Fisher’s exact test and antibody 
titres were correlated with age using the Kendall’s rank correlation test and mean titres were 
compared between symptomatic and asymptomatic participants using the Wilcoxon rank sum 
test.  
 
Variables associated with SARS-CoV-2 positivity were analysed using univariate and 
multivariable analyses to identify predictors of SARS-CoV-2 seropositivity. Initially all possible 





data, and the Mann-Whitney U test for continuous data (continuous data were skewed). All 
variables were then included in a weighted binary multivariable logistic regression model. 
Participants with incomplete CRFs were excluded from univariate and multivariable analysis. 
Analysis was conducted in R (R Core Team, 2014). 
 
Patient and Public Involvement (PPI) 
A PPI group comprising parents and children was convened. The PPI group met virtually and 
via socially distanced meetings. The group contributed to the design of the study through 
online surveys and video discussions. They have also contributed to media interviews on 
national television and the lead young person has co-authored a manuscript outlining their 
experience of taking part in the study (27).  
 
Office for Research Ethics Committees (OREC) and local Research Governance  
Ethical approval was obtained from the London - Chelsea Research Ethics Committee (REC 
Reference - 20/HRA/1731) and the Belfast Health & Social Care Trust Research Governance 
(Reference 19147TW-SW).  
 
Study Registration 
This study was registered at https://www.clinicaltrials.gov (trial registration: NCT0434740) on 
the 15/04/2020 (last updated 27/05/20). At the time of registration no patients had been 













In total, 1042 potential participants were screened for inclusion, of whom 35 were excluded; 
18 were outside the specified age range, 1 met specific exclusion criteria, and 16 declined 
consent. The remaining 1007 children were enrolled, of which 15 were excluded from analysis 
due to unsuccessful phlebotomy; 992 were included in the final analysis (Figure 1). The 
recruitment by site is shown in Table 2. In the analysis cohort 962/992 (97%) had complete 
CRFs and 30/992 (3%) had partially complete CRFs.  
 
The median age of participants was 10·1 years (range 2.03 to 15.99 years), with 484 (49%) 
aged under 10 years; 509 (51%) were male. The roles of participant’s parents are shown in 
Figure 2. There were 359/992 (36.2%) children of hospital medical staff, 191/992 (19.3%) 
children of hospital nursing/midwifery staff, 95/992 (9.6%) children of community medical staff, 
36/992 (3.6%) children of community nursing staff and 160/992 (16.1%) children of other 
patient facing staff such as radiographers, physiotherapists and other allied healthcare 
professionals. There were 151/992 (15.2%) children of non-patient facing staff such as 
managerial and administrative staff.  
 
There were 68/992 participants with positive SARS-CoV-2 antibodies, giving a seroprevalence 
of 6.9% (95% CI 5.4 to 8.6, n=992). Of those with positive SARS-CoV-2 antibody tests, 34/68 
(50%) reported no symptoms. The most commonly reported symptoms associated with SARS-
CoV-2 seropositivity were fever 21/68 (31%), gastrointestinal symptoms (diarrhoea, vomiting 
and abdominal cramps) 13/68 (19%) and headache 12/68 (18%). The presence of fever, 
cough or changes in a sense of smell/taste were recorded in 26/68 (38%) of participants. No 
children within this cohort had severe disease requiring hospital admission. A summary of 
reported symptoms and their frequency can be seen in Table 3. 
 
Seroprevalence of SARS-CoV-2 antibodies varied between sites. Belfast had significantly 





in London seroprevalence was significantly higher than all other sites at 11.6% (95% CI 7.8 to 
16.8 n=199); p=0.0069. The remaining 3 sites reported seroprevalence rates between 5.6% 
and 8.9%. The difference between these 3 sites were not statistically significant (Table 2). 
 
The mean antibody titres, for those testing positive, were; 
 4.86 Calculated index S/C (95%CI 4.28 to 5.45, n=58) for the Abbott Architect® 
SARS-CoV-2 IgG assay. 
 65.32 cut-off index COI (95% CI 43.24 to 87.40, n=31) for the Roche Elecsys® Anti-
SARS-CoV-2 Total Antibody assay. 
 64.17 AU/ml (95% CI 37.99 to 90.36, n=31) for the DiaSorin LIAISON® SARS CoV-2 
S1/S2 IgG assay.  
 
There was no correlation between age and antibody titres (Figure 3). The results from the 
Abbott Architect® SARS-CoV-2 IgG assay indicated a small but significant difference in mean 
antibody titres between asymptomatic 4.3 S/C (95% CI 3.4 to 5.2) and symptomatic 
participants 5.5 S/C (95% CI 4.7 to 6.2); p=0.04. There was no significant difference in mean 
antibody titres for the Roche Elecsys® or DiaSorin LIAISON® assays when comparing 
symptomatic and asymptomatic participants (p =0.23 and 0.58 respectively) (Figure3). A table 
of concordance between the three assays used is available in the supplementary material. 
 
The univariate analysis of individual variables associated with SARS-CoV-2 seropositivity is 
shown in Table 3. In addition to clinical features, variables such as age, gender, the role of 
the parent (patient facing or not) and known household contacts were included. Age and 
gender were not significantly associated with SARS-CoV-2 seropositivity (Table 3). Parental 
role showed significant association in the univariate analysis, but this was no longer significant 
once corrected for site and other variables in the multivariable analysis. Contact with a 
household member with confirmed SARS-CoV-2 infection was significantly associated with 





(Table 3). The multivariable analysis identified 4 variables independently associated with 
SARS-CoV-2 seropositivity: (i) known household contact with confirmed SARS-CoV-2 
(p<0.0001), (ii) fatigue (p=0.001), (iii) gastrointestinal symptoms (p=0.0001), and (iv) changes 

































This observational study is one of the largest UK studies of paediatric SARS-CoV-2 antibody 
seroprevalence, and the only study to recruit from all regions of the UK. Following the first 
pandemic wave in the UK, 68/992 (6.9%) children of healthcare workers had evidence of prior 
infection with SARS-CoV-2. Whilst this is likely to be higher than the general population it is 
surprisingly similar to the seroprevalence reported by the Office for National Statistics (ONS) 
study of adults from England and Wales (6.2%) (10), and similar to international estimates 
(11-13). As expected there was marked geographical variation, with London reporting the 
highest seropositivity rates (11.6%) and Belfast the lowest (0.9%) p<0.0001. These regional 
variations are consistent with published adult estimates of seroprevalence from the same time 
period (10).  
 
In this study there was a near equal number of children under 10 years of age 32/68 (47%) 
and children over 10 years of age 36/68 (53%) developing antibodies consistent with previous 
SARS-CoV-2 infection. Age, as a categorical or continuous variable, was not a statistically 
significant factor in predicting the presence of antibodies, or the overall titres in children 
irrespective of the assay used (Figure 3).  
 
Of the 68 participants with positive antibody tests, 34/68 (50%) reported no symptoms. The 
most commonly reported symptoms associated with SARS-CoV-2 seropositivity were fever 
(21/68) 30% and gastrointestinal symptoms 13/68(19%). These symptoms, in addition to 
fatigue, and changes in sense of smell or taste, were independently associated with previous 
SARS-CoV-2 seropositivity based on the weighted binary multivariable regression modelling. 
These findings reflect a number of international studies (15-20). Current UK testing strategies 
directing testing only for those with fever, cough or changes in smell/taste would have 
identified 26/34 (76%) of symptomatic participants in this study (assuming 100% sensitivity 





identified nearly all symptomatic cases in this cohort 33/34(97%). It is however, important to 
note that the predictive value of individual symptoms is context dependent and their utility will 
vary dependent upon the season and the symptomatology of other circulating infections. 
These findings may be useful to policy makers when considering the best approach to 
screening paediatric populations for SARS-CoV-2. 
 
There is evidence from adult serological studies that those with severe illness develop a 
significantly greater antibody response than those with mild or asymptomatic disease (28-30). 
This has raised concerns that children, who typically have mild disease, may fail to develop a 
meaningful antibody response to SARS-CoV-2 infection. More recently, emerging adult data 
suggest that even asymptomatic adults are capable of mounting a potentially lasting and 
protective immune response (31-32). In our study antibody titres, measured using the Abbott 
Architect® SARS-CoV-2 IgG assay, were significantly higher in symptomatic children 
compared with asymptomatic children p=0.04. These findings were not replicated with either 
the Roche Elecsys® Anti-SARS-CoV-2 or DiaSorin LIAISON® SARS CoV-2 S1/S2 IgG 
assays. It therefore remains unclear to what extent the severity of symptoms in children 




















The strengths of this study are that it is a large multicentre study including children from across 
the four nations of the UK. The findings are based on systematically screening children for 
SARS-CoV-2 antibodies and this removes selection bias from the assessment of the 
asymptomatic proportion and determine symptomatology. 
 
The limitations of this study are: 
 The SARS-CoV-2 antibody tests have not been validated for use in children 
 The absolute sample size of seropositive participants is relatively small  
 There was selection bias towards children of hospital staff and children with only mild 
disease. 




This study demonstrates that approximately half of children with positive antibody tests for 
SARS-CoV-2 reported no symptoms. This study also demonstrates that younger children were 
just as likely to have SARS-CoV-2 antibodies as older children and that they are capable of 












What is known about this topic? 
 Children are relatively unaffected by the SARS-CoV-2 infection with very few 
requiring hospitalisation. 
 A large, but unknown proportion of children with SARS-CoV-2 infection are 
asymptomatic. 
 Molecular testing of oral/nasal swabs underestimates SARS-CoV-2 infection. 
 
What this study adds  
 Gastrointestinal upset is a relatively common symptom of Covid-19 in children. Adding 
gastrointestinal upset to the list of symptoms triggering a test in children would improve 
case-finding.  
 Asymptomatic and mildly symptomatic children are capable of developing an antibody 
response to SARS-CoV-2.  
 This study did not find a difference in rates of seropositivity or antibody 
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Figure 3: Scatter diagrams of age/symptoms in children of healthcare workers and SARS-
CoV-2 assay titre. Abbott Architect® reported in S/C, Roche Elecsys® reported in COI, DiaSorin 








Table 1: Summary of antibody tests used 
Name of assay Target Units Cut-Off 
Abbott Architect® SARS-CoV-2 IgG Nucleocapsid Calculated index 
S/C 
1.4 S/C 
Roche Elecsys® Anti-SARS-CoV-2 Nucleocapsid Cut-off index 
COI 
1.0 COI 










Table 2: Recruitment summary of children of healthcare workers and seroprevalence by site (n and 
(%) unless otherwise stated) 
 
Site Screened Included Participants Antibody Positive %* 
Belfast 217 215 2 0.9(0.2 to 3.3) 
Cardiff 192 178 10 5.6(3.1 to 10.0) 
Glasgow 229 224 20 8.9(5.9 to 13.4) 
London 215 199 23 11.6(7.8 to 16.8) 
Manchester 189 176 13 7.4(4.4 to 12.2) 
Total 1042 992 68 6.9(5.4 to 8.6) 





















Table 3: Univariate analysis of variables for SARS-CoV-2 Antibodies in children of healthcare workers 
(Fisher’s Exact for categorical variables, Mann-Whitney U for continuous variables). Number and (%) 

































Median age (years) 992(100) 10.1(5.8) 10.2(6.9) - 0.481 
Aged 10 years and over 992(100) 472(51) 36(53) 1.1(0.6 to 1.8) 0.802 
Male gender 991(99.9) 468(51) 41(60) 1.5(0.9 to 2.5) 0.133 
Parents (patient contact) 992(100) 789(85) 52(76) 0.6(0.3 to 1.1) 0.055 
Confirmed household contact 960(97) 63(7) 30(44) 10.9(6.1 to 19.6) <0.0001 
Fever 962(97) 102(11) 21(31) 3.5(1.9 to 6.2) <0.0001 
Gastrointestinal Symptoms 962(97) 31(3) 13(19) 6.6(3.0 to 13.8) <0.0001 
Headache 962(97) 34(4) 12(18) 5.4(2.4 to 11.4) <0.0001 
Lethargy/fatigue 962(97) 8(1) 9(13) 16.8(5.5 to 51.9) <0.0001 
Cough 962(97) 90(10) 7(10) 1.03(0.38 to 2.3) 1.000 
Change in sense of smell/taste 962(97) 7(1) 5(7) 10.0(2.4 to 37.8) <0.0008 
Myalgia/arthralgia 962(97) 21(2) 5(7) 3.3(0.94 to 9.4) 0.031 
Sore throat  962(97) 41(5) 5(7) 1.7(0.5 to 4.4) 0.367 
Shortness of breath 962(97) 13(1) 3(4) 3.1(0.6 to 11.8) 0.098 
Coryza 962(97) 27(3) 1(1) 0.5(0.0 to 3.0) 0.715 
Rash 962(97) 10(1) 1(1) 1.3(0.0 to 9,5) 0.556 
Conjunctivitis 962(97) 1(0) 0(0) 0.0(0.0 to 508.7) 1.000 
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